Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Integrative Analysis of Gene Functions in Cellular and Animal Models of Pancreatic Cancer (CAM-PAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Spain,Switzerland,Germany,Germany,Italy,Germany,Germany,Germany,Netherlands,United Kingdom,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2018-10-31
Duration (months): 60.0
Total project cost (EUR): 14691297.34
EU funding (EUR): 11193108.0
Participants: 15
Project status: CLOSED

Cancers are genetic disease arising from the accumulation of multiple molecular alterations in affected cells. Large-scale genomic, transcriptomic and proteomic analyses have established comprehensive catalogues of molecules which are altered in their structure and/or abundance in malignant tumors as compared to healthy tissues. Far less developed are concepts and methods to integrate data from different sources and to directly interrogate gene functions on a large scale in order to differentiate “driver” alterations, which directly contribute to tumor progression, from indolent “passenger” alterations. As a consequence, examples of successful translation of knowledge generated from “omics” approaches into novel clinical concepts and applications are scarce. Pancreatic cancer is a prime example of this dilemma. Representing the 4th to 5th most common cause of cancer related deaths, it is a disease with a major socioeconomic impact. Despite enormous advances in the identification of molecular changes associated with the disease, new treatment options have not emerged. Thus, 5-year survival rates remain unchanged at a dismal 6%, the lowest for all solid tumors. Using pancreatic cancer as a model disease, the goal of this integrative project is to develop novel cellular and animal models, as well as novel strategies to generate, analyze and integrate large scale metabolic and transcriptomic data from these models, in order to systematically characterize and validate novel targets for therapeutic intervention. In addition to the general tumor cell population, special consideration will be given to sub-populations of tumor-initiating cells, a.k.a. tumor stem cells. To this end, the consortium comprises i) SMEs with strong focus on technology development, ii) clinical and academic partners with extensive experience in pancreatic cancer molecular biology and management of pancreatic cancer patients, and iii) technology and data analysis experts from academic groups.

Keywords: genetic basis of pancreatic cancer,novel cellular and animal models,integration of large scale metabolic,transcriptomic and genetic data,development of market-ready technologies and prototypes
New Molecular-Functional Imaging Technologies and Therapeutic Strategies for Theranostic of Invasive Aspergillosis (MATHIAS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Germany,France,Switzerland,Denmark,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2018-09-30
Duration (months): 60.0
Total project cost (EUR): 7831318.88
EU funding (EUR): 5987541.0
Participants: 6
Project status: CLOSED

The development of novel technologies to diagnose and clinically treat invasive Aspergillus fumigatus infections is the scope of this research consortium. A. fumigatus is a ubiquitous mould whose spores are airborne and thus frequently inhaled. Humans with impaired immunity, e.g. those with haematological malignancies or bone marrow transplant recipients, are at a dramatically increased risk of severe, invasive A. fumigatus infection known as invasive aspergillosis (IA). IA is a rare disease in Europe but causes tremendous costs to the public health sector. Currently definitive diagnosis of IA is only obtained at autopsy or relies on invasive biopsy, an extremely unpleasant procedure which is not always applicable in suffering patients. Thus, a convenient, fast and specific diagnosis of IA is not available forcing clinicians to administer antifungal drugs on spec if a standard antibiotic treatment failed to reduce fever in risk patients. It would be of high financial benefit for clinics and has the potential to increase the survival rates of immuno-compromised patients, if a definitive diagnosis of IA could be obtained early and its response to treatment be monitored. This would allow applying the correct therapy at a dose and duration exactly tailored to patient needs. Equally important is the development of new treatment options which can replace existing systemic antifungal drugs with their known severe side effects. The approach of the consortium is to develop new disease specific tracers based on monoclonal antibodies along with the combined molecular imaging technologies PET/MR and PET/CT. Newly developed tracers shall then be functionalised by a combined labelling with radio-isotopes allowing diagnostic PET imaging but also immuno-radiotherapy, thus representing truly anti-infectious theranostics. This would provide a framework for new tools in the management not only of this rare but life-threatening mycosis but principally also for other infectious hazards.

Keywords: aspergillosis,simultaneous pet/mr,2-photon microscopy,chelator,radioisotopes,diagnose and treatment,theranostic
Advanced Studies towards Knowledge on Lyssavirus Encephalitis Pathogenesis Improving Options for Survival (ASKLEPIOS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Czechia,Poland,Hungary,Hungary,Belgium,France,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2016-10-31
Duration (months): 36.0
Total project cost (EUR): 4072356.4
EU funding (EUR): 2994881.0
Participants: 10
Project status: CLOSED

The overall aim of ASKLEPIOS is to unravel and increase our understanding of the mechanisms that govern pathogenesis of rabies virus (RABV) infection, in pursuit of the rational identification of novel therapeutic leads for rabies encephalitis. Several studies have been conducted over the past decades attempting to unravel the pathogenesis of this deadly disease, however with limited success. New knowledge on the mechanisms of the RABV life-cycle and interaction with the host is needed to identifying clinically applicable therapeutic leads, in search of rational intervention strategies. The project objectives are to: 1. Identify molecules that inhibit RABV replication 2. Identify molecules that inhibit detrimental host responses to RABV infection: 3. Show whether opening the blood-brain-barrier (BBB) improves treatment efficacy: 4. Validate the potential of the molecules identified under 1 and 2 to be used as post-exposure prophylaxis (PEP) when classical PEP is ineffective. In pursuit of these objectives ASKLEPIOS will perform in vitro screening of the anti-viral effect of type-I IFNs, MAP kinase inhibitors and siRNAs. Second, the therapeutic potential of inhibiting the pyroptotic pathway and inflammatory response will be investigated by using inhibitors of caspase-1, IL-1β, TNF-α IL-6 and MAP kinases. Third, the capacity of molecules to reach the brain will be first evaluated using an efficient in vitro BBB system and in vivo mouse studies.. The most efficient molecule to open the BBB will be co-administrated with the selected therapeutic molecules in the subsequent stages of the project. The results will be collected and synthesized and tested in mice to identify the most effective approach. The ability to clear infection and recover from rabies will be evaluated for each therapeutic scheme identified

Keywords: rabies,pathogenesis,encephalitis,therapy
Cancer Vaccine development for Hepatocellular Carcinoma (HEPAVAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Germany,Italy,France,United Kingdom,Spain,Belgium
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2019-08-31
Duration (months): 72.0
Total project cost (EUR): 8201226.48
EU funding (EUR): 5996110.8
Participants: 10
Project status: CLOSED

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. Given the lack of available effective treatments, the overall prognosis for HCC patients is poor, with a dismal 5-year survival of 5-6%. The main goal of this proposal is to develop a therapeutic cancer vaccine aiming at improving clinical outcome in early-stage HCC patients after loco-regional ablative therapy. HepaVac is an European consortium of academic, SME and pharmaceutical company partners with complementary and substantial expertise in cancer immunotherapy and vaccine development. The main objective of HepaVac is to develop a novel cancer vaccine approach for HCC based on epitopes naturally processed and presented by HLA class I and II (HLA-ligandome), to elicit both CD4+ T helper and CD8+ CTL tumor-specific effector and memory responses. The HCC HLA-ligandome will be identified in primary tumor tissues using a combined and integrated approach, developed and thoroughly validated by Partners #2 and #5. The selected peptide epitopes will constitute the candidate cancer vaccine for HCC, aiming at covering the broadest haplotype diversity with a multi-epitope and multi-TAA strategy. T cell epitopes derived from universal TAA and unique patient-specific mutated antigens will allow the design of a prime-boost vaccine strategy based either on a prime-boost schedule made of an “off-the-shelf” T cell epitope cocktail or on a schedule where the boost is complemented by a “personalized” T cell epitope cocktail. Both epitope cocktails will be adjuvanted in a novel and potent immunomodulator developed by Partner #6. Such a vaccination strategy will be tested in a randomized controlled multi-center phase I/II human clinical trial, assessing as primary endpoints safety and induction of specific cellular immune responses and, as secondary endpoints, OS and PFS of patients receiving the vaccine after tumor ablation vs tumor ablation alone.

Keywords: hepatocellular carcinoma,multi-epitope cancer vaccine,hla-ligandome,immunomonitoring,phase i/ii vaccine clinical trial
Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Spain,Ireland,Netherlands,Germany,Austria,France,France,Spain
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2017-08-31
Duration (months): 48.0
Total project cost (EUR): 8178399.4
EU funding (EUR): 6000000.0
Participants: 11
Project status: CLOSED

The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the processes of fibroblast differentiation to myofibroblasts, the predominance of collagen synthesis over degradation and/or collagen maturation may allow for interstitial repair, thus providing a new strategy for the prevention and treatment of adverse cardiac remodeling involved in the transition to and the progression of heart failure. From a large body of existing multi-omics, literature data and previous hypothesis-driven research conducted by members of the consortium, a number of specific extracellular and intracellular targets have been identified whose involvement in MIF is beginning to be understood and that may be targeted by specific therapies. The specific aims of the Fibro-Targets are: (i) To provide further evidence on the mechanisms of action of the above targets (ii) To validate experimentally that new anti-fibrotic strategies can be developed based on the above targets (iii) To approach the potential clinical scenario of the above targets for HF therapy To reach these aims the following studies will be performed: (i) Observational and interventional experimental studies in already existing and/or de novo generated appropriate in vitro and in vivo models. (ii) Clinical studies, stratifying large scale populations of patients available to the consortium, at risk to develop HF and likely to be responsive to specific novel and/or exiting anti-fibrotic therapies. The stratification will be based on specific “fibrogenetic” phenotypic profiles using multi-panel imaging and circulating markers descriptive of mechanisms involving the proposed novel targets.

Keywords: myocardial interstitial fibrosis (mif),anti-fibrotic strategies,heart failure
GAbapentin in Paediatric Pain (GAPP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Italy,Netherlands,Italy,Italy,Estonia,United Kingdom,Germany,Albania,France,Italy,Spain,Greece
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-07-01
End date: 2017-06-30
Duration (months): 48.0
Total project cost (EUR): 7191562.85
EU funding (EUR): 5476875.0
Participants: 17
Project status: CLOSED

Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate medicinal products, in clinical practice paediatric patients are often under-treated causing profound impact on their QoL. To date, opioids, non-steroid anti-inflammatory drugs (NSAIDs), antidepressants and anticonvulsants are used to treat pain, but only few of these include a paediatric authorisation. In addition, the few available paediatric drugs have a very different authorisation profile across Europe and, when not approved in paediatrics, they are used off-label to cover the high therapeutic need, thus exposing children to unnecessary risks of dosing errors and increasing ADRs. The GAPP Project is focused on the development of gabapentin for the treatment of paediatric chronic pain, a condition where gabapentin, as demonstrated in adults, is expected to bring great benefit to children. To this end, a large international scientific Consortium is set up, with experienced professionals in the field of pain that will work together with a Pharmaceutical Company committed to apply for a PUMA using the project results. Within GAPP, age-appropriate formulation will be developed and two randomised, comparator-controlled clinical trials and a bridging study will be conducted in compliance to a submitted Paediatric Investigation Plan (PIP, Summary Report Day 90 - EMEA-001310-PIP01-12) in order to investigate appropriate dosages, efficacy and safety of gabapentin in the paediatric population. Further to this, in order to ensure the safety of gabapentin in very young children, a non clinical study will be conducted to evaluate the neurotoxic potentil of the drug. At the end of the project, gabapentin can be proposed for treatment of chronic pain in children both as monotherapy and as adjuvant therapy.

Keywords: gabapentin,pain,chronic,paediatrics,paediatric formulation
Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves (TRANSLINK)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,France,France,Spain,United Kingdom,Israel,Sweden,Italy,United States
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2018-02-28
Duration (months): 54.0
Total project cost (EUR): 8025983.47
EU funding (EUR): 5996971.0
Participants: 14
Project status: CLOSED

TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bioprosthetic Heart Valve (BHV) implants. 300,000 patients/year benefit from BHV, a major healthcare problem (second most frequent cardiac surgery). BHV clinical outcome suffers from late dysfunctions restricting their application to older recipients. Based on a retrospective (already computerised) and prospective cohort of approximately 3,000 BHV recipients and control patients from 3 large EU cardiac surgery groups, TRANSLINK aims primarily to establish the possible role of recipients' immune response (IR) against BHV as a major cause to mid- to-long term clinical dysfunction. Precise molecular analysis of preimplantation BVH sugar moieties will be performed. Possible indirect side-effects on BHV endocarditis and host vessels inflammation are secondary end points. Serial and trans-sectional blood samples will be dispatched to a battery of highly specialised partner groups for testing anti-Gal, -Neu5Gc and -hyaluronic acid antibodies (Ig) using both validated and newly designed screening tools, glycan array patterns, and macrophages/NK responses. Data will be crossed with clinical outcome scores. Project design aims at delivering comprehensive recommendations in the time-frame of the grant. Fundamental basic science progress in the field of carbohydrate antigens is also expected. Furthermore, prevention (BHV from engineered animal source lacking major antigens) and treatment (bioabsorbants of deleterious Ig) oriented remedies as well as prospective biomarkers of longterm BHV deterioration will be set up by three first-class SMEs. TRANSLINK may strongly impact the treatment of heart valve diseases by improving morbid-mortality in patients with heart valves diseases and increasing the indication of BHV to younger patients.

Keywords: bioprosthetic heart valves (bhv),cardiac surgery,premature bhv failure,adverse immune reactions,immunological studies,novel biological heart valves,novel therapeutic strategies.
Comparing the effectiveness of palliative care for elderly people in long term care facilities in Europe (PACE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Belgium,United Kingdom,Italy,Finland,Poland,Netherlands,Netherlands,Belgium,Luxembourg,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2019-01-31
Duration (months): 60.0
Total project cost (EUR): 7082671.4
EU funding (EUR): 5566140.0
Participants: 14
Project status: CLOSED

Aging populations, rising costs and sustainable delivery of high-quality care are increasingly common concerns in all EU countries. PACE aims to perform comparative effectiveness research concerning palliative care in long term care facilities (LTCFs) in Europe. While a growing number of older people will require palliative care in institutionalized settings, palliative care has only recently begun to be developed in LTCFs and effectiveness research hardly exists. PACE aims to compare, in six EU countries (BE, UK, IT, FI, PL, NL) (1) the effectiveness of health care systems with and without formal palliative care structures in LTCFs on patient and family outcomes –quality of dying, quality of life– quality of palliative care and cost-effectiveness, by performing a representative cross-sectional study in 48 LTCFs per country to include at least 1,152 deceased residents (2) the impact of the UK palliative care health service intervention Route to Success on patient outcomes, family and staff in LTCFs, by performing a controlled cluster trial across the six countries, randomly allocating 24 LTCFs to intervention and 24 to control. The PACE consortium brings together leading academic partners from multiple disciplines with EU organizations/networks actively tapping into the most important professional groups and policy-makers in the field, making it possible to influence research, practice, policy and public at national and international level in and beyond participating PACE countries. PACE will help to achieve the objectives of the European 2020 Strategy, specifically the European Innovation Partnership on Healthy and Active Aging. Based on its study results, PACE will develop tools to assist practitioners and policy and decision-makers to make evidence-based decisions regarding best palliative care practices in LTCFs. This will ultimately lead to optimizing the delivery of palliative care to the large proportion of EU citizens living and dying in old age.

Keywords: comparative effectiveness research palliative care long-term care quality of end of life care needs of older people
Vaccination In Atherosclerosis (VIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,Sweden,Sweden,Austria,Sweden,France,United Kingdom,Switzerland,United States,Denmark,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-12-01
End date: 2018-11-30
Duration (months): 60.0
Total project cost (EUR): 8136785.57
EU funding (EUR): 5994233.0
Participants: 12
Project status: CLOSED

Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underlying pathology of CVD and atherosclerosis is responsible for 70% of all cases of CVD. Extensive studies into the pathology of atherosclerosis show that its etiology is found in a combination of dyslipidemia and a related inflammatory response with an established autoimmune component, while the major cause of acute CVD events, plaque rupture, due to an inflammatory destabilization of the atherosclerotic lesion. CVD is therefore an autoimmune-like disease in the context of a metabolic disease. Thus far, therapeutic approaches in CVD have been focused at normalizing dyslipidemia in order to lower plasma cholesterol. Statins and additional surgical approaches such as angioplasty have achieved a 30% risk reduction for CVD during the last 10-15 years. However, additional approaches to improve the treatment of dyslipidemia by for instance improving the level of the anti-atherogenic lipoprotein HDL have failed in a number of clinical trials. This implicates that new therapeutic approaches are urgently needed to narrow down the remaining 70% risk for CVD. We aim to develop a new immunomodulatory treatment, a therapeutic vaccine that permanently restores the immune balance within the arterial wall by inhibiting the inflammatory responses during atherosclerosis. The VIA consortium aims to develop a vaccine, dissect the immune pathways underlying the beneficial effect of the vaccine, optimize the vaccine, test its safety and perform a phase I clinical trial using the atheroprotective vaccine. The vaccine is foreseen to result in a substantial lowering of the risk for CVD.

Keywords: therapeutic vaccine cardiovascular disease (cvd) atherosclerosis plaque rupture adjuvant ldl (low-density lipoprotein)